suPARnostic® is a prognostic biomarker useful for risk stratification of acute medical patients in the Emergency Department.

Important clinical benefits include;

  • Prioritization: Identifies patients who can be discharged after treatment
  • Safety: Identifies high-risk patients wih unaffected vital signs
  • Cost savings: Shortens the average patient-length-of-stay and reduces
    the cost of healthcare


The suPARnostic® TurbiLatex product is approved for the Roche Diagnostics Cobas c111 system.

ViroGates is currently validating the suPARnostic® TurbiLatex on other turbidimetric high throughput instruments including the Cobas c500 and c700 series, commonly used in diagnostic laboratories.
Expected CE-IVD approval on Roche Cobas c502 / c702 to be ready primo 2019.

See also the News announcement here.


suPARnostic® TurbiLatex Reagents


The suPARnostic® TurbiLatex test is a turbidimetric immunoassay that quantitatively determines suPAR in human plasma/serum samples.

The suPARnostic® TurbiLatex product is validated for the Roche Cobas c111 turbidimetric platform.

Validation on other turbidimetric platforms will follow.
Expected CE-IVD approval on Roche Cobas c502 / c702
to be ready primo 2019.

Product contains:
The reagents are ready-to-use.
The kit contains 20 mL of R1 and 8 mL of R2, sufficient for 100 tests including dead volume.


  • Ready-to-use reagents
  • Automated, high throughput operation
  • Standarized test adding to the menu breadth
  • Timely results
  • LIS connectivity


Product Code

Product no. T001: suPARnostic® TurbiLatex Reagents


Price Quote

Please fill in the form here and we will send you a price quote



Helpful documents

Performance Characteristics 
Please see the Instructions for Use above.

More information about Sales & Support of suPARnostic® products here; How To Buy